Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy

Launched by SHANGHAI GENERAL HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Sep 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how changes in Prostate-Specific Antigen (PSA) levels in the fluid collected from the abdomen after prostate surgery (called peritoneal drainage fluid) can help predict outcomes for men with prostate cancer. Prostate cancer is a common type of cancer in men, and surgery to remove the prostate is a standard treatment. While doctors usually check PSA levels in the blood to monitor the disease, this study hopes to understand how PSA levels in the drainage fluid can provide valuable information for better follow-up care and treatment decisions after surgery.

To participate in this study, men must have been treated for prostate cancer with a radical prostatectomy. However, those who received certain treatments before surgery or experienced urine leakage after the operation will not be eligible. If you join this trial, you'll help researchers learn more about prostate cancer and potentially improve how patients are monitored after surgery. The study is currently not recruiting participants, but it's an important step toward finding better ways to manage prostate cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prostate cancer patients treated with radical prostatectomy
• Exclusion Criteria:
• • 1. Received neoadjuvant endocrine/chemotherapy before surgery;
• • 2. Urine leakage after surgery (positive creatinine test of drainage fluid).